The development of a novel transcatheter arterial infusion chemotherapy and significance of combination with molecular targeted agents

我们设计了一种新的经导管动脉灌注化疗作为肝细胞癌的经血管治疗，不使用固体栓塞材料，并使用碘油和可降解淀粉微球（DSM）。我们在临床试验中使用顺铂来研究这种疗法的有效性。在这项研究中，我们研究了这种新的肝动脉灌注化疗的有效性，使用米铂与阿托碘油的亲和力优于顺铂。2011年，我们开始了一项前瞻性随机研究，分为两组（DSM非联合组，DSM联合组）。到目前为止，我们治疗了30例。目前，DSM联合组无进展生存期有延长的趋势，DSM联合组有效率高。我们认为这种治疗方法是一种新的肝动脉灌注化疗方法。

We designed a novel transcatheter arterial infusion chemotherapy as transvascular treatment for hepatocellular carcinoma, without the use of a solid embolic material, and the use of lipiodol and degradable starch microspheres (DSM). We investigated the efficancy of this therapy using cisplatin in clinical trial. In this study, we examined the usefulness of this new hepatic arterial infusion chemotherapy using miriplatin affinity with lipiodol better than cisplatin. In 2011, we start a prospective randomized study by two groups (DSM non-combination group, DSM combination group). So far, we treated in 30 cases. At the moment, progression-free survival tend to extended in DSM combination group, andresponse rate to be high in DSM combination group. We think this treatment is useful as a new hepatic arterial infusion chemotherapy.